STX4 as A Potential Drug Target for Parkinson's and Addiction

Target Name: STX4

NCBI ID: G6810

STX4

STX4 as A Potential Drug Target for Parkinson's and Addiction

Syntaxin 4 (STX4), also known as Transcript Variant 3, is a protein that is expressed in the brain and is involved in the function of dopamine (neurotransmitter) in the brain. STX4 has been identified as a potential drug target for the treatment of various neurological disorders, including Parkinson's disease and addiction.

The STX4 protein is a member of the syntaxin family, which includes several other proteins that are involved in the regulation of intracellular signaling pathways. The syntaxin family has been identified as a potential drug target for the treatment of various neurological disorders due to its involvement in the regulation of neurotransmitter signaling pathways.

STX4 is expressed in the brain and is involved in the function of dopamine in the brain. Dopamine is a neurotransmitter that plays a crucial role in the regulation of mood, motivation, and pleasure. STX4 is involved in the regulation of dopamine signaling pathways, which are important for the proper functioning of the brain.

Studies have shown that STX4 is involved in the regulation of dopamine signaling pathways in the brain. For example, one study published in the journal NeuroImage in 2012 used techniques such as immunofluorescence to show that STX4 was expressed in the brain and was involved in the regulation of dopamine signaling pathways.

Another study published in the journal Molecular Psychiatry in 2019 found that STX4 was involved in the regulation of dopamine signaling pathways in the brain and that its levels were decreased in individuals with Parkinson's disease. The study suggested that STX4 may be a potential drug target for the treatment of Parkinson's disease.

In addition to its involvement in the regulation of dopamine signaling pathways, STX4 has also been shown to be involved in the regulation of other neurotransmitter signaling pathways. For example, one study published in the journal Neuropharmacology in 2016 found that STX4 was involved in the regulation of serotonin signaling pathways in the brain.

STX4 has also been shown to be involved in the regulation of the ion channels in the brain. For example, one study published in the journal Brain Research in 2018 used techniques such as patch-electrode recordings to show that STX4 was involved in the regulation of the ion channels in the brain.

Based on the above findings, STX4 is considered a potential drug target (or biomarker) for the treatment of various neurological diseases, including Parkinson's disease and addiction. Future studies can further explore the function of STX4 in the nervous system and study its role in the treatment of neurological diseases.

Protein Name: Syntaxin 4

Functions: Plasma membrane t-SNARE that mediates docking of transport vesicles (By similarity). Necessary for the translocation of SLC2A4 from intracellular vesicles to the plasma membrane (By similarity). In neurons, recruited at neurite tips to membrane domains rich in the phospholipid 1-oleoyl-2-palmitoyl-PC (OPPC) which promotes neurite tip surface expression of the dopamine transporter SLC6A3/DAT by facilitating fusion of SLC6A3-containing transport vesicles with the plasma membrane (By similarity). Together with STXB3 and VAMP2, may also play a role in docking/fusion of intracellular GLUT4-containing vesicles with the cell surface in adipocytes and in docking of synaptic vesicles at presynaptic active zones (By similarity)

The "STX4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STX4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets